483 related articles for article (PubMed ID: 29721686)
1. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
3. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
[TBL] [Abstract][Full Text] [Related]
4. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
5. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
[TBL] [Abstract][Full Text] [Related]
6. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
7. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
[TBL] [Abstract][Full Text] [Related]
9. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
[TBL] [Abstract][Full Text] [Related]
10. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
12. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
[TBL] [Abstract][Full Text] [Related]
13. Association Between Gadoxetic Acid-Enhanced Magnetic Resonance Imaging, Organic Anion Transporters, and Farnesoid X Receptor in Benign Focal Liver Lesions.
van Rosmalen BV; Visentin M; Furumaya A; van Delden OM; Kazemier G; van Gulik TM; Verheij J; Stieger B
Drug Metab Dispos; 2024 Jan; 52(2):118-125. PubMed ID: 38050024
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
[No Abstract] [Full Text] [Related]
15. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
Bröker MEE; Taimr P; de Vries M; Braun LMM; de Man RA; Ijzermans JNM; Dwarkasing RS
AJR Am J Roentgenol; 2020 Jan; 214(1):81-89. PubMed ID: 31573852
[No Abstract] [Full Text] [Related]
16. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
[TBL] [Abstract][Full Text] [Related]
17. Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors.
Tselikas L; Pigneur F; Roux M; Baranes L; Costentin C; Roche V; Calderaro J; Herin E; Laurent A; Zafrani E; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2017 Mar; 42(3):825-832. PubMed ID: 27704147
[TBL] [Abstract][Full Text] [Related]
18. Quantification of liver fat content in liver and primary liver lesions using triple-echo-gradient-echo MRI.
Nougaret S; Monsonis B; Molinari N; Riviere B; Piron L; Kassam Z; Cassinotto C; Guiu B
Eur Radiol; 2020 Sep; 30(9):4752-4761. PubMed ID: 32318848
[TBL] [Abstract][Full Text] [Related]
19. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background.
Yoneda N; Matsui O; Kitao A; Kozaka K; Kobayashi S; Sasaki M; Yoshida K; Inoue D; Minami T; Gabata T
Radiographics; 2016; 36(7):2010-2027. PubMed ID: 27740898
[TBL] [Abstract][Full Text] [Related]
20. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
